Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.05 USD
Change Today -0.0019 / -3.73%
Volume 15.0K
ISLT On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

islet sciences inc (ISLT) Snapshot

Open
$0.05
Previous Close
$0.05
Day High
$0.05
Day Low
$0.05
52 Week High
09/10/14 - $0.39
52 Week Low
07/30/15 - $0.04
Market Cap
3.3M
Average Volume 10 Days
38.5K
EPS TTM
--
Shares Outstanding
66.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ISLET SCIENCES INC (ISLT)

Related News

No related news articles were found.

islet sciences inc (ISLT) Related Businessweek News

No Related Businessweek News Found

islet sciences inc (ISLT) Details

Islet Sciences, Inc., a biotechnology company, is engaged in the research, development, and commercialization of new medicines and technologies for the treatment of metabolic diseases and related indications covering unmet medical needs. The company offers ISLT-P, an implantable suspension of encapsulated insulin-producing porcine islet cells for the treatment of insulin-dependent diabetes; ISLT-2669, a novel lead IL-12 small molecule inhibitor selected for preclinical development for treatment of type 2 diabetes; and ISLT-LSF Analogs, a library of small molecule lisofylline analogs that block inflammatory actions of cytokines, which destroy insulin-producing beta cells for diabetes and diabetes-related complications. It is also involved in developing ISLT-Bdx, a PCR based molecular diagnostic measuring hypomethylated beta cell-derived DNA as a biomarker of beta cell loss for the early detection of type 1 diabetes or onset of insulin dependent type 2 diabetes. In addition, the company develops Remogliflozin, a selective SGLT2 inhibitor in Phase II clinical development for type 2 diabetes and nonalcoholic steatohepatitis. Islet Sciences, Inc. was founded in 2010 and is based in Raleigh, North Carolina.

3 Employees
Last Reported Date: 07/28/14
Founded in 2010

islet sciences inc (ISLT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $75.0K
Chief Operating Officer, Director and Chairma...
Total Annual Compensation: $75.0K
Compensation as of Fiscal Year 2014.

islet sciences inc (ISLT) Key Developments

Islet Sciences, Inc. expected to report Fiscal Year 2015 results on August 4, 2015. This event was calculated by Capital IQ (Created on July 29, 2015).

Islet Sciences, Inc. expected to report Fiscal Year 2015 results on August 4, 2015. This event was calculated by Capital IQ (Created on July 29, 2015).

Islet Sciences, Inc Announces Resignation of Executive Officers

On July 22, 2015, Islet Sciences, Inc. announced resignation of Steven Delmar as Chief Financial Officer of the company and all subsidiaries effective August 15, 2015. On July 23, 2015, Mr. James Green also resigned as Chief Executive Officer of the company and all subsidiaries effective August 22, 2015. On July 23, 2015, Dr. William Wilkison resigned as Chief Operating Officer of the company and all subsidiaries effective August 22, 2015. Wilkison did not resign from the board of directors.

Islet Sciences, Inc. Receives the Temporary Restraining Order from the District Court, Clark County, Nevada

On June 30, 2015 petitioners John Steel (a Director of Islet), Jonathan Lakey, Edward T. Gibstein, Anthony Reed, Robert Bantle, D&D Funding Florida, LLC, and Stephen Cohen filed a lawsuit in the District Court, Clark County Nevada to order a shareholders meeting and to issue a temporary restraining order. A hearing was held on July 6, 2015 and on July 7, 2015 the court ordered a shareholders meeting to be held within sixty days and agreed to the petitioners request for a temporary restraining order pending the receipt of security for the temporary restraining order and the order itself. On July 14, 2015, Islet Sciences, Inc. received the temporary restraining Order from the District Court, Clark County, Nevada. The order restrains and enjoins the company from taking any actions outside the ordinary course of business and from undertaking any further transfers or encumbrances of the company’s assets, or taking any actions which might be dilutive to current shareholders. The company intends to defend against this action and believes it is without merit. There is a hearing on the petitioner’s motion for preliminary injunction on July 20, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISLT:US $0.05 USD -0.0019

ISLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ISLT.
View Industry Companies
 

Industry Analysis

ISLT

Industry Average

Valuation ISLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISLET SCIENCES INC, please visit www.isletsciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.